Google Chrome
Safari
Firefox
Edge
Devices
Hovione offers simple, patented and globally competitive dry powder inhalers – Disposable, Capsule, Blister and Large Dose DPIs – which are available for fully integrated turn-key development with formulation and for licensing.
Search
News / Jul 23, 2021
Hovione signs the COP26 manifest to stop climate changes
BCSD Portugal, 23 July 2021
Press Release / Jan 17, 2023
Hovione is recognized as a Top Employer 2023
This certification is a recognition of Hovione´s resolve to put people first, and a validation that the investment in HR excellence is delivering.
News / Sep 09, 2024
Hovione Commits to Science-Based Targets for Greenhouse Gas (GHG) Emissions
Hovione commitment to setting SBTs in line with the Paris Agreement
Article / Oct 20, 2020
The Coronavirus Crisis: Challenges and Opportunities for CMOs, CDMOs and CROs
CheManager, 20 October 2020
Press Release / Mar 07, 2023
Hovione receives the 2023 CDMO Leadership Award in all six categories and is Champion in Compatibility and Expertise
Hovione won the 2023 CDMO Leadership Award across all six categories across all three groups of respondents
Press Release / Oct 27, 2025
Hovione Completes Initial $100M Investment Cycle to Expand U.S. Operations at New Jersey Manufacturing Site
Investment More Than Doubles Capacity for Spray Drying, a Critical Solubility Enhancement Technology That Could Benefit the Development of 70% of Drugs*
Press Clipping / Nov 12, 2018
How Hovione grew from a basement lab to a global pharmaceutical services company
C&EN, November 12, 2018